CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
Levetiracetam +1 moredrug
Likely dose
Levetiracetam 750 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00849862
NCT00849862Phase 1Completed
CompareCT.gov

Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Levetiracetam 750 mg Tablet and Keppra® (Reference) Following a 750 mg Dose in Healthy Subjects Under Fasting Conditions

Teva Pharmaceuticals USA·interventional·Posted Feb 24, 2009·Updated Sep 11, 2009

In Brief

A Phase 1 clinical trial evaluating Levetiracetam and Keppra® for Healthy. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The objective of this study is to compare the rate and extent of absorption of a test formulation of Levetiracetam and the reference Keppra® administered as a 1 x 750 mg tablet under fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
Collaborators--

Timeline

Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 24, 2009
Enrollment StartOct 1, 2005
Primary CompletionNov 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.4 years ago

Interventions

Levetiracetamdrug

750 mg Tablet

Keppra®drug

750 mg Tablet